eISSN: 2473-0815
Submit manuscript...
Review Article Volume 13 Issue 3
Tirzepatide: A revolutionary dual-action therapy for type 2 diabetes mellitus and beyond
Abhijit Trailokya
Received: October 29, 2025 | Published: November 12, 2025
Citation: Trailokya A. Tirzepatide: A revolutionary dual-action therapy for type 2 diabetes mellitus and beyond. Endocrinol Metab Int J. 2025;13(3):84-89. DOI: 10.15406/emij.2025.13.00376
Abstract
Tirzepatide is a groundbreaking dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, offering a transformative approach to managing Type 2 Diabetes Mellitus (T2DM), obesity and now sleep apnoea. Tirzepatide recently approved and marketed in India. This manuscript delves into the clinical efficacy, mechanism of action, and potential impact of Tirzepatide on glycemic control and weight reduction based on recent clinical trials and real-world evidence. With its unique dual-incretin action, Tirzepatide represents a significant advancement in the therapeutic landscape, offering superior outcomes in HbA1c reduction and sustained weight loss compared to traditional therapies.
Keywords: tirzepatide, weight management, hba1c, mounjaro, zepbound
©2025 Trailokya. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.